AAKASH GOYAL ET AL: "Recent discoveries and emerging therapeutics in eosinophilic esophagitis", WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS, vol. 7, no. 1, 1 January 2016 (2016-01-01) , pages 21-23, XP055641171, ISSN: 2150-5349, DOI: 10.4292/wjgpt.v7.i1.21 (B1)

US-A1- 2015 017 176 (B1)

Celgene: "Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis - NCT02098473 -", ClinicalTrials.gov, 28 March 2014 (2014-03-28), pages 1-5, XP055641137, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T02098473?term=nct02098473&draw=1&rank=1 [retrieved on 2019-11-11] (B1)

DE ROOIJ WILLEMIJN E. ET AL: "Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review", DRUGS, vol. 79, no. 13, 27 July 2019 (2019-07-27) , pages 1419-1434, XP93027361, NZ ISSN: 0012-6667, DOI: 10.1007/s40265-019-01173-2 Retrieved from the Internet: URL:https://curedfoundation.org/wp-content /uploads/2020/08/de-Rooij-Drugs-2019-EoE-t reatment-review-1.pdf> (B1)

DELLON EVAN S. ET AL: "Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol. 19, no. 3, 1 March 2021 (2021-03-01), pages 473-483, XP93027360, AMSTERDAM, NL ISSN: 1542-3565, DOI: 10.1016/j.cgh.2020.03.036 (B1)

DELLON et al.: "Development And Field Testing Of A Novel Patient-Reported Outcome Measure Of Dysphagia In Patients With Eosinophilic Esophagitis", Alimentary pharmacology & therapeutics, vol. 38, no. 6, 2013, pages 634-642, XP055437034, (B1)

GANN PETER H ET AL: "An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 146, no. 2, 11 May 2020 (2020-05-11), page 367, XP086238595, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2020.03.045 [retrieved on 2020-05-11] (B1)

HIRANO I ET AL: "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY RPC4046 IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, vol. 121, no. 5, 2018, XP085539284, ISSN: 1081-1206, DOI: 10.1016/J.ANAI.2018.09.047 (B1)

HIRANO IKUO ET AL: "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 156, no. 3, 2 November 2018 (2018-11-02), page 592, XP085592307, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2018.10.051 (B1)

HIRANO, I: "ACG Midwest Postgraduate Course, Eosinophilic Esophagitis", Feinberg school of medicine , 2013, pages 1-28, XP055581310, Retrieved from the Internet: URL:https://gastroupdates.files.wordpress. com/2016/11/eoe.pdf [retrieved on 2017-08-30] (B1)

LEECH et al.: "Regulation of p53 by Macrophage Migration Inhibitory Factor in Inflammatory Arthritis", Arthritis & Rheumatology, vol. 48, no. 7, 2003, pages 1881-1889, XP055437030, (B1)

MARC E. ROTHENBERG ET AL: "Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 135, no. 2, 1 February 2015 (2015-02-01), pages 500-507, XP055190922, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2014.07.049 (B1)

SCHOEPFER et al.: "How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?", The American journal of gastroenterology, vol. 110, no. 3, 3 March 2015 (2015-03-03) , pages 402-414, XP055437048, (B1)

TRIPP CATHERINE S ET AL: "RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 [alpha]1 and [alpha]2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 34, no. 6, 28 April 2017 (2017-04-28) , pages 1364-1381, XP036256558, ISSN: 0741-238X, DOI: 10.1007/S12325-017-0525-8 [retrieved on 2017-04-28] (B1)

US-A1- 2013 096 096 (B1)

US-A1- 2014 341 913 (B1)

COLLINS et al.: "Eosinophilic Esophagitis (EoE) Histologic Changes More Strongly Associate with Treatment Status Than Peak Eosinophil Count (PEC", Journal of Allergy and Clinical Immunology, vol. 135, no. 2, 2015, XP055437052, (B1)